OptometricManagement.com
While 40% to 60% of symptomatic dry eye patients have significant inflammation, traditional testing methods, such as tear breakup time and Schirmer’s, can’t predict which patients they are.1,2 Yet, differentiating the “haves” from the “have nots” is essential for clinicians.
Matrix metalloproteinase-9 (MMP-9), a biomarker for inflammation, is elevated in the tears of patients with dry eye disease (DED). InflammaDry (Quidel) is the first and only rapid in-office test that detects MMP-9 in tears.
(OptometricManagement.com, Special Section, July 2018)